Macitentan and Shock haemorrhagic - a phase IV clinical study of FDA data

Summary:

Shock haemorrhagic is reported as a side effect among people who take Macitentan (macitentan), especially for people who are female, 40-49 old, have been taking the drug for 1 - 6 months also take Remodulin, and have Primary pulmonary hypertension.

The phase IV clinical study analyzes which people have Shock haemorrhagic when taking Macitentan. It is created by eHealthMe based on reports of 7,368 people who have side effects when taking Macitentan from the FDA, and is updated regularly.

What is Macitentan?

Macitentan has active ingredients of macitentan. eHealthMe is studying from 7,371 Macitentan users. Check the latest studies of Macitentan.

What is Shock haemorrhagic?

Shock haemorrhagic (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin due to excess bleeding) is found to be associated with 658 drugs and 799 conditions by eHealthMe. Check the latest studies of Shock haemorrhagic.

On Jul, 18, 2026

7,368 people reported to have side effects when taking Macitentan.
Among them, 12 people (0.16%) have Shock haemorrhagic.

Could Macitentan cause Shock haemorrhagic?

Among these 12 people:

How long have people been on Macitentan when they have Shock haemorrhagic? *

What is the gender of people who have Shock haemorrhagic when taking Macitentan? *

female: 90.91 %
male: 9.09 %

What is the age of people who have Shock haemorrhagic when taking Macitentan? *

What are other drugs people take besides Macitentan? *

What are other side effects people have besides Shock haemorrhagic? *

Post Procedural Haemorrhage (post procedural bleeding): 11 people, 91.67%
Haemorrhage Subcutaneous (bleeding from skin): 11 people, 91.67%
Upper Gastrointestinal Haemorrhage (upper gastrointestinal bleeding): 1 person, 8.33%
Thrombocytopenia (decrease of platelets in blood): 1 person, 8.33%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 1 person, 8.33%
Melaena (the passage of black, tarry stools): 1 person, 8.33%
Leukocytosis (increased white blood cells): 1 person, 8.33%
Hypotension (abnormally low blood pressure): 1 person, 8.33%
Hepatic Failure (liver failure): 1 person, 8.33%
Hepatic Encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure): 1 person, 8.33%

What are the existing conditions these people have? *

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 11 people, 91.67%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 6 people, 50.00%

* Approximation only. Some reports may have incomplete information.

Do you take Macitentan and have Shock haemorrhagic?

- Check whether Shock haemorrhagic is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Macitentan:

Macitentan (7,371 reports)

Browse all side effects of Macitentan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Shock haemorrhagic:

Shock haemorrhagic (659 drugs)

Browse all the conditions that are associated with Shock haemorrhagic:

Shock haemorrhagic (799 conditions)

Related publications that referenced our studies

Hwabejire JO, Lu J, Liu B, Li Y, Halaweish I, Alam HB, "Valproic acid for the treatment of hemorrhagic shock: a dose-optimization study", journal of surgical research, 2014 Jan .
Hwabejire JO, Lu J, Liu B, Li Y, Halaweish I, Alam HB, "Valproic acid for the treatment of hemorrhagic shock: a dose-optimization study", journal of surgical research, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on macitentan (the active ingredients of Macitentan) and Macitentan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.